PT Hetzer Medical Indonesia Tbk (IDX:MEDS)
Indonesia · Delayed Price · Currency is IDR 72.00
-3.00 (-4.00%)
At close: Feb 27, 2026
IDX:MEDS Revenue
PT Hetzer Medical Indonesia Tbk had revenue of 1.80B IDR in the quarter ending September 30, 2025, with 36.33% growth. This brings the company's revenue in the last twelve months to 4.58B, down -73.50% year-over-year. In the year 2024, PT Hetzer Medical Indonesia Tbk had annual revenue of 6.39B, down -71.87%.
Revenue (ttm)
4.58B
Revenue Growth
-73.50%
P/S Ratio
24.55
Revenue / Employee
286.38M
Employees
16
Market Cap
112.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.39B | -16.33B | -71.87% |
| Dec 31, 2023 | 22.72B | -15.01B | -39.79% |
| Dec 31, 2022 | 37.74B | -38.05B | -50.21% |
| Dec 31, 2021 | 75.79B | -12.00B | -13.67% |
| Dec 31, 2020 | 87.79B | 75.77B | 630.26% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PT Kalbe Farma Tbk. | 34.38T |
| PT Siloam International Hospitals Tbk | 12.51T |
| PT Soho Global Health Tbk | 10.51T |
| PT Millennium Pharmacon International Tbk | 3.99T |
| PT Sejahteraraya Anugrahjaya Tbk | 3.30T |
| PT Phapros Tbk | 856.09B |
| PT Royal Prima Tbk | 332.14B |
| PT Indofarma Tbk | 206.24B |